India has approved two more COVID-19 vaccines and the antiviral drug Molnupiravir under emergency use authorisation, Union Health Minister Mansukh Mandaviya tweeted.
About:
Currently, India uses Covishield, Covaxin and Sputnik V for vaccination.
Corbevax, to be made by Hyderabad-based Biological E, is a protein subunit vaccine, and Covovax, to be manufactured by the Serum Institute of India, Pune, is a nanoparticle-based vaccine.
Corbevax has been co-developed by Biological E, the Baylor College of Medicine in Houston, U.S., and the U.S. company Dynavax Technologies. Covovax is produced by the Serum Institute of India under licence from Novavax, a U.S.-based biotechnology company.
The vaccine has been approved by the World Health Organization (WHO) under its Emergency Use Listing and, therefore, will be available globally as part of the COVAX initiative to ensure that at least 40% of world is vaccinated on priority.
Molnupiravir, which was approved this month by the U.S. Food and Drugs Administration (USFDA), close on the heels of Paxlovid by Pfizer Inc, is said to be a promising drug for those with mild and moderate disease and also easily administered as a pill. Thirteen companies in India are set to manufacture it.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
